New England Research & Management Inc. boosted its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 12.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,152 shares of the biopharmaceutical company’s stock after purchasing an additional 5,405 shares during the quarter. Bristol-Myers Squibb makes up 1.8% of New England Research & Management Inc.’s portfolio, making the stock its 14th biggest holding. New England Research & Management Inc.’s holdings in Bristol-Myers Squibb were worth $3,079,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $26,000. GoalVest Advisory LLC bought a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $29,000. Coppell Advisory Solutions Corp. bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $31,000. Live Oak Investment Partners bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $33,000. Finally, Strengthening Families & Communities LLC raised its position in shares of Bristol-Myers Squibb by 90.0% during the 1st quarter. Strengthening Families & Communities LLC now owns 475 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 225 shares during the period. 74.98% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the transaction, the executive vice president now directly owns 27,868 shares in the company, valued at $1,706,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the transaction, the executive vice president now directly owns 27,868 shares in the company, valued at $1,706,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert M. Plenge sold 732 shares of the business’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total value of $44,754.48. Following the transaction, the executive vice president now owns 6,584 shares in the company, valued at $402,545.76. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.
Analyst Ratings Changes
Bristol-Myers Squibb Stock Performance
Shares of NYSE BMY traded up $0.75 during trading hours on Thursday, hitting $60.40. 907,823 shares of the company’s stock were exchanged, compared to its average volume of 8,782,318. Bristol-Myers Squibb has a 1-year low of $59.45 and a 1-year high of $81.43. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.39 and a quick ratio of 1.28. The stock has a market capitalization of $126.18 billion, a price-to-earnings ratio of 15.87, a PEG ratio of 1.58 and a beta of 0.42. The company’s 50-day moving average price is $61.88 and its 200-day moving average price is $65.33.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing the consensus estimate of $1.99 by ($0.24). Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The business had revenue of $11.23 billion for the quarter, compared to analyst estimates of $11.81 billion. During the same period in the prior year, the firm posted $1.93 EPS. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. On average, sell-side analysts expect that Bristol-Myers Squibb will post 7.49 earnings per share for the current fiscal year.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
- Five stocks we like better than Bristol-Myers Squibb
- Stock Market Sectors: What Are They and How Many Are There?
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- Insider Trades May Not Tell You What You Think
- Shutterstock is the Value Stock they don’t want you to know about
- What Does the Consumer Price Index Measure?
- 3 Low-Cost ETFs That Are Crushing SPY
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.